This anatomical feature can reduce injection discomfort, but absorption kinetics differ: buttock injections typically show slower peak plasma concentration than abdominal injections, which may affect symptom onset timing
SURMOUNT trials showed tirzepatide produces sustained weight loss 1520% greater than semaglutide at comparable treatment intervals
However, it simultaneously promotes lactate production, which may activate TGF- signaling and contribute to fibrogenesis [106]
Clinical outcomes associated with drugs for obesity and overweight: a systematic review and network meta-analysis of randomized controlled trials
2025 (Diabetes Care) confirm 14% fewer MACE, 13% fewer CV deaths, 12% fewer all-cause deaths, 9% fewer heart-failure hospitalizations, and 17% fewer renal composites with GLP-1RA [39, 40]